Cart
sales@molnova.com
VUT-MK142
CAS No. 1313491-22-3
VUT-MK142( —— )
Catalog No. M22884 CAS No. 1313491-22-3
VUT-MK142 is a new cardiomyogenic small molecule promoting the differentiation of pre-cardiac mesoderm into cardiomyocytes,which may be useful to differentiate stem cells into cardiomyocytes for cardiac repair.VUT-MK142 was identified as the most promising candidate with respect to cardiomyogenic activity.?
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 106 | Get Quote |
|
| 5MG | 177 | Get Quote |
|
| 10MG | 267 | Get Quote |
|
| 25MG | 537 | Get Quote |
|
| 50MG | 745 | Get Quote |
|
| 100MG | 1035 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameVUT-MK142
-
NoteResearch use only, not for human use.
-
Brief DescriptionVUT-MK142 is a new cardiomyogenic small molecule promoting the differentiation of pre-cardiac mesoderm into cardiomyocytes,which may be useful to differentiate stem cells into cardiomyocytes for cardiac repair.VUT-MK142 was identified as the most promising candidate with respect to cardiomyogenic activity.?
-
DescriptionVUT-MK142 is a new cardiomyogenic small molecule promoting the differentiation of pre-cardiac mesoderm into cardiomyocytes,which may be useful to differentiate stem cells into cardiomyocytes for cardiac repair.VUT-MK142 was identified as the most promising candidate with respect to cardiomyogenic activity.?Treatment using this novel agent induced the strongest up-regulation of expression of the cardiac marker ANF in both P19 embryonic carcinoma cells and C2C12 skeletal myoblasts.?The activity of VUT-MK142 on this marker superseded CgC;?moreover, the novel compound significantly up-regulated the expression of other cardiac markers, and promoted the development of beating cardiomyocytes from cardiovascular progenitor cells.
-
In VitroVUT-MK142 possesses promising cardiomyogenic effects on various cell types. VUT-MK142 shows a remarkable effect on both P19 and C2C12 cells. Compared to CgC, VUT-MK142-treatment leads to a markedly stronger up-regulation of the expression of ANF.VUT-MK142 (1 μM, 7 day treatment) significantly (p < 0.05) increases the luciferase signal by 3.1 ± 0.3 luciferase (n = 5)-fold in P19 cells.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1313491-22-3
-
Formula Weight298.4
-
Molecular FormulaC17H22N4O
-
Purity>98% (HPLC)
-
SolubilityDMSO:25 mg/mL (83.79 mM; Need ultrasonic)
-
SMILESCOC1=CC=C(NC2=CC(NC3CCCCC3)=NC=N2)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Moumita Koley, et al. VUT-MK142 : a new cardiomyogenic small molecule promoting the differentiation of pre-cardiac mesoderm into cardiomyocytes. Medchemcomm. 2013 Aug 1;4(8):1189-1195.
molnova catalog
related products
-
Nelivaptan
Nelivaptan is a non-peptide vasopressin receptor antagonist, it is selective for the V1B subtype.
-
Petunidin-3-O-glucos...
Petunidin-3-O-glucoside chloride has significantly higher antioxidant activity than the Fe2+ control. Petunidin-3-O-glucoside causes problems in digestibility, may be important dietary supplements with beneficial health effects.
-
Inclacumab
Inclacumab, a humanized monoclonal IgG4 antibody (Anti-Human Selectin P Recombinant Antibody), specifically binds to P-selectin with a dissociation constant (Kd) of 9.9 nM.
